Sulfonylureas

Sulfonylureas are a class of oral glucose-lowering medications that stimulate insulin secretion by the pancreatic beta cell and have played a central role in the history of treatment for type 2 diabetes mellitus. For many decades, together with metformin, they were one of the cornerstones of pharmacological treatment for hyperglycemia because of their good glycemic efficacy, low cost and very widespread global availability. They still retain a genuine clinical role today, especially in settings where glycated hemoglobin control is a priority, financial resources are limited, access to newer medications is restricted, or there are specific reasons to favor a potent, rapid-acting secretagogue. Their contemporary role can no longer be interpreted according to past paradigms, however, because the introduction of classes with a lower risk of hypoglycemia, less impact on body weight and demonstrated cardiovascular or renal benefits has profoundly changed the therapeutic hierarchy.

From an epidemiological perspective, sulfonylureas remain among the most widely prescribed antidiabetic medications worldwide, especially in healthcare systems in which cost is a fundamental determinant of treatment selection. The class is heterogeneous, however, in both pharmacokinetic profile and hypoglycemic risk, and cannot be regarded as a single undifferentiated group. Agents such as gliclazide, glimepiride, glipizide and glibenclamide, or glyburide, share the same basic mechanism but differ in duration of action, potency, route of elimination, risk of prolonged hypoglycemia and appropriateness in vulnerable populations. A modern monograph on sulfonylureas must therefore explain not only why they work, but also why they are now selected more selectively, with close attention to age, kidney function, meal patterns, hypoglycemic risk, cardiovascular comorbidities and overall therapeutic goals.

Sulfonylureas arise from a very direct pathophysiological rationale: in type 2 diabetes mellitus, a substantial proportion of hyperglycemia results from the beta cell's inability to produce insulin secretion adequate for the degree of insulin resistance. During many stages of the disease, the pancreas is not yet completely exhausted, but the early secretory response is attenuated, the postprandial peak is insufficient and overall compensation is inadequate. In this setting, a medication capable of rapidly increasing insulin release can effectively reduce both fasting blood glucose and postprandial hyperglycemia, at least while residual beta-cell mass remains capable of responding to stimulation.

This explains why sulfonylureas are effective mainly in type 2 diabetes mellitus with residual beta-cell function and why they are instead ineffective or essentially inappropriate in type 1 diabetes mellitus and forms of diabetes characterized by absolute insulin deficiency. Their effect depends on the presence of viable beta cells. They do not replace insulin and do not correct insulin resistance itself. Rather, they enhance insulin release from a beta cell that still exists but can no longer respond adequately to the metabolic load.

Their position has changed in contemporary diabetology. The most recent guidelines no longer regard them as the mandatory step after metformin or the universal reference for oral therapy. Initial selection and subsequent intensification now depend largely on the presence of atherosclerotic cardiovascular disease, heart failure, chronic kidney disease, obesity, frailty, hypoglycemic risk and individual priorities. In this setting, sulfonylureas have lost prominence because they do not offer documented specific cardiorenal benefits comparable to those of sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide 1 receptor agonists, and because their principal clinical limitation remains the risk of hypoglycemia, often accompanied by weight gain.

This does not mean that the class has become irrelevant. Sulfonylureas retain a specific function in many patients. They may be useful when a rapid reduction in glycated hemoglobin is needed, when the patient's glycemic profile is driven more by a secretory defect than by severe obesity, when cost substantially limits treatment access, or when other medications are not tolerated or unavailable. They may also be used as add-on therapy to metformin or other classes in selected patients, provided that hypoglycemic risk is assessed carefully.

The key point is therefore selective prescribing. Up-to-date prescribing does not select “the sulfonylurea” in the abstract, but identifies the patient in whom the immediate glucose-lowering benefit outweighs the limitations in safety and durability. In other words, the class should no longer be interpreted as a standard solution for type 2 diabetes mellitus, but as a pharmacological tool to be used judiciously, favoring agents with a better tolerability profile and lower hypoglycemic risk in appropriate settings.

The mechanism of action of sulfonylureas centers on the adenosine triphosphate-sensitive potassium channel, known as K_ATP, located on the pancreatic beta-cell membrane. Under physiological conditions, glucose entry into the beta cell, its phosphorylation, mitochondrial metabolism and the increase in the adenosine triphosphate-to-adenosine diphosphate ratio cause this channel to close, leading to membrane depolarization, opening of voltage-dependent calcium channels, calcium influx and subsequent exocytosis of insulin granules. Sulfonylureas exploit this same system but activate it pharmacologically by binding to the channel's receptor subunit, the sulfonylurea receptor 1, or SUR1, and inducing channel closure even in the absence of an adequate glucose-dependent metabolic signal.

The clinical consequence of this mechanism is fundamental: insulin is released relatively independently of the prevailing blood glucose level. This explains both the efficacy of the class and its main risk. If insulin secretion is stimulated when glucose is high, the result is therapeutic; if it is stimulated when food intake is low, a meal is skipped, the patient undertakes unplanned physical activity, or kidney function declines and slows medication clearance, the result may be hypoglycemia that is sometimes severe and prolonged.

At the cellular level, sulfonylureas do not increase insulin sensitivity, do not directly reduce hepatic glucose production and do not correct metabolic inflammation or lipotoxicity. Their target remains the secretory defect. They are therefore particularly effective while exploitable beta-cell reserve is still present, whereas their durability progressively declines as the disease advances. The progressive loss of beta-cell mass and function in type 2 diabetes mellitus ultimately limits the pancreas's ability to respond to pharmacological stimulation over time.

Receptor biology also explains some differences among individual agents. Sulfonylureas are not completely interchangeable with respect to receptor affinity, half-life, active metabolites and interaction with similar channels in other tissues. Over time, this has fueled debate about the cardiovascular safety of the class and differences between older and newer agents. The prevailing interpretation today is that the evidence does not justify indiscriminate condemnation of the entire class, but does require caution in generalizing the profile of one agent to all others.

From a pathophysiological perspective, sulfonylureas are therefore the classic example of medications that improve the glycemic value by acting on a genuine disease mechanism without profoundly altering its course. They are potent but not strictly physiological, because they stimulate insulin release through a mechanism that is less finely modulated by glucose than the incretin pathway. This is precisely why they remain effective but require more careful use, especially when the therapeutic objective is not simply to lower glycated hemoglobin, but to do so at the lowest possible cost in terms of hypoglycemia, weight gain and management complexity.

Sulfonylureas are traditionally divided into first- and second-generation medications, a distinction that is now mainly historical but helps explain the evolution of the class. First-generation medications, such as tolbutamide and chlorpropamide, have progressively lost clinical importance because of a less favorable pharmacokinetic profile and greater risk of adverse events. Contemporary practice focuses almost exclusively on second-generation sulfonylureas, particularly glibenclamide, or glyburide, glipizide, gliclazide and glimepiride.

Although these agents share the same pharmacological target, they are not equivalent. Glibenclamide has historically been potent but carries a higher and more prolonged hypoglycemic risk, especially in older adults and people with kidney failure. Glipizide has a relatively shorter duration of action and is often considered easier to manage in patients at risk of accumulation. Gliclazide, particularly in its modified-release formulation, is often highlighted in the literature as one of the options with the best balance between efficacy and safety within the class. Glimepiride is widely used internationally and has substantial efficacy and an established role, but still requires caution in frail patients, older adults and those with kidney disease.

These differences result from pharmacokinetic and pharmacodynamic variables. Some agents have active metabolites, whereas others do not. Some depend more heavily on renal elimination, while others have a mixed profile. The duration of the insulinotropic effect varies, and with it the risk of late or nocturnal hypoglycemia. Equally important is the patient's adherence to a regular meal pattern. A long-acting medication in a person who skips meals or eats irregularly creates a very different setting from that of a patient with a stable, predictable eating routine.

The clinical pharmacology of the class therefore requires avoiding an oversimplified concept of “equivalent dose.” Switching from one agent to another cannot be performed as though it were merely a change of brand, because hypoglycemic risk and overall tolerability may change substantially. Titration must also be individualized. Sulfonylureas are not medications that should be rapidly pushed to the maximum dose through prescribing inertia; the aim is to use the lowest effective dose capable of improving the glycemic profile with the least possible risk.

Another relevant pharmacological consideration is the interaction with kidney function. Not all sulfonylureas are equally suitable in chronic kidney disease. The most cautious recommendations suggest selecting agents with a lower tendency to accumulate when the class is necessary and progressively reducing the dose as renal vulnerability increases. This point is crucial because declining kidney function not only increases medication exposure but also reduces endogenous insulin clearance and attenuates counterregulatory capacity, thereby amplifying hypoglycemic risk.

The classic indication for sulfonylureas is type 2 diabetes mellitus when diet, physical activity and other nonsecretagogue medications are insufficient to achieve glycemic goals, or when financial or organizational constraints make it necessary to select an effective, available oral medication that is relatively straightforward to prescribe. The class is particularly useful when a patient's hyperglycemia is sustained by residual but insufficient insulin secretion and a rapid reduction in glycated hemoglobin is needed.

The phenotype in which sulfonylureas may make the most sense does not necessarily correspond to the patient with the greatest obesity and insulin resistance. In that setting, weight gain and the absence of favorable effects on insulin resistance often make other strategies preferable. Sulfonylureas may instead be particularly effective in relatively lean or normal-weight people with type 2 diabetes mellitus and a predominantly secretory defect, in whom increasing endogenous insulin can substantially improve glycemic control, at least for a period of time.

In many clinical settings, the class also retains an important role as second- or third-line therapy when metformin, sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists or dipeptidyl peptidase 4 inhibitors are not tolerated, are contraindicated or are inaccessible because of cost, reimbursement or availability. In this sense, sulfonylureas are not “second-rate” medications, but tools that remain highly relevant in real-world medicine, where treatment sustainability strongly influences choices.

There are also particular settings in which some sulfonylureas acquire a highly specific role. A classic example is certain forms of monogenic diabetes, particularly some subtypes of neonatal diabetes caused by mutations of the K_ATP channel, in which sulfonylureas may permit transition from insulin to oral therapy with extraordinary results. This specialist use should not be confused with their routine use in type 2 diabetes mellitus, but it demonstrates especially clearly the biological power of the class mechanism when the molecular defect being targeted is precisely in the channel itself.

Relative and absolute contraindications depend on careful selection, however. An older person who lives alone, has irregular meals, impaired kidney function, previous hypoglycemic episodes and limited ability to recognize symptoms is a poor candidate. A person at high cardiovascular risk, in whom the priority is organ protection in addition to glycemic control, is often better served by other classes. A patient whose work carries substantial risk, such as professional driving or hazardous duties, requires particular caution because of the danger of unrecognized hypoglycemia.

Sulfonylureas should therefore be viewed as medications with high potential but high prescribing responsibility. The correct question is not whether the class lowers blood glucose, because it does so with recognized efficacy; the appropriate question is in which patients the benefit of that glycemic reduction can be achieved with acceptable risk and with added value consistent with the available alternatives.

Sulfonylureas have robust glucose-lowering efficacy. In most studies, they reduce glycated hemoglobin by approximately 1% to 1.5%, and sometimes more in patients with very high baseline values. This result explains their historical success and why they continue to be perceived as “powerful” medications. Improvement involves both fasting and postprandial blood glucose, although the specific effect varies according to the agent, duration of action, meal distribution and presence of other concomitant therapies.

Glycemic potency, however, does not equate to durability of benefit. One of the best-known limitations of the class is the progressive loss of efficacy over time. This phenomenon results partly from the natural history of type 2 diabetes mellitus, with progressive decline in beta-cell function, and partly from the fact that the medication does not modify the underlying pathogenic process. The beta cell may respond well during the early or intermediate stages, but over the years its ability to produce adequate insulin secretion through pharmacological stimulation alone diminishes.

Historical studies, such as the United Kingdom Prospective Diabetes Study, showed that intensive glycemic control based on sulfonylureas or insulin reduces microvascular complications compared with a less intensive strategy. This finding profoundly shaped the history of diabetology because it established that effective lowering of blood glucose is clinically useful. Subsequent studies have shown, however, that glucose reduction alone is not sufficient to ensure a consistent macrovascular benefit and that the price paid in hypoglycemia can become relevant, especially in complex patients.

The class has not demonstrated intrinsic cardiorenal benefits comparable to those observed with other, newer therapies. This does not mean that it is globally harmful in every patient, but it requires a fundamental conceptual distinction: sulfonylureas are effective medications for glycemic control, not medications selected primarily for organ protection. More recent cardiovascular safety studies, such as CAROLINA for glimepiride, have helped reassure clinicians that some agents do not show an excess of major cardiovascular events compared with active comparators, but this is not equivalent to demonstrating an inherent cardiovascular benefit.

In clinical practice, therefore, the efficacy of the class should be interpreted on two levels. From a strictly metabolic perspective, sulfonylureas remain highly effective. From an overall strategic perspective, they are less attractive when the priority goals include weight loss, reduction of hypoglycemic risk, cardiovascular protection, kidney protection or simplification of therapy in a frail patient. Modern assessment of their efficacy therefore cannot be limited to glycated hemoglobin alone, but must integrate the overall clinical context.

Starting sulfonylurea therapy requires a much more careful preliminary assessment than was often performed in the past. Before prescribing the medication, clinicians must clarify meal patterns, regularity of food intake, kidney function, biological age, presence of liver failure, the patient's ability to recognize symptoms of hypoglycemia and any occupational or personal exposure to serious consequences should a hypoglycemic episode occur. Correct prescribing begins with this assessment, not with the simple observation that glycated hemoglobin is above target.

Whenever possible, agent selection should favor options with a better safety profile. In many contemporary clinical settings, gliclazide or glimepiride is preferred over glibenclamide, particularly to reduce the risk of severe and prolonged hypoglycemia. Glipizide also retains a role in some patients, particularly when a relatively shorter duration of action is desired. Although glibenclamide was historically used very widely, it now requires particular caution and should be avoided in many older adults.

Titration should be gradual. Sulfonylureas should not be started with the aim of rapidly reaching the maximum dose, but with the intention of finding the lowest dose capable of producing sufficient glycemic benefit. An excessive dose not only increases hypoglycemic risk, but also tends to promote weight gain and complicate meal management. In general, early reassessment of the clinical and laboratory response is preferable to aggressive escalation.

The timing of administration depends on the agent and meal pattern. Some sulfonylureas are taken once daily, whereas others benefit from division into multiple doses, but in every case the patient must understand precisely how the medication relates to meals. This educational aspect is crucial. Pharmacologically correct treatment can become dangerous if the patient skips breakfast, eats late, fasts voluntarily or reduces caloric intake because of intercurrent illness without knowing how to adapt.

Titration must be even more cautious in combination regimens. If a sulfonylurea is added to metformin, efficacy may be substantial but the risk of weight gain increases. If it is combined with insulin, the overlap of two insulinotropic or replacement therapies may substantially increase the risk of hypoglycemia and often requires reducing the dose of one component or discontinuing the sulfonylurea when insulin treatment becomes more intensive.

Proper treatment planning therefore extends beyond the initial prescription. It includes selecting the agent, defining goals, providing the minimum essential nutritional education, identifying warning signs and anticipating how the medication should be modified if food intake declines, kidney function worsens or treatment becomes more complex. Without this preliminary work, an effective sulfonylurea can become an apparently simple but clinically insidious medication.

The most important adverse event of the entire class is hypoglycemia. This is not a marginal side effect, but the feature that more than any other defines the difference between sulfonylureas and many newer classes. Sulfonylurea-induced hypoglycemia may be mild and easily corrected, but it may also be severe, prolonged and recurrent, especially with long-acting agents or those with active metabolites, in older adults, people with kidney disease, malnourished patients, those who consume excessive alcohol or have irregular eating patterns. Unlike other therapies, the risk here depends not only on dose, but on the interaction among dose, caloric intake, kidney function and the patient's counterregulatory capacity.

Clinical manifestations of hypoglycemia range from adrenergic symptoms, including tremor, sweating, intense hunger, palpitations and anxiety, to neuroglycopenic presentations with confusion, speech disturbances, behavioral changes, focal deficits, seizures, loss of consciousness and secondary trauma from a fall or accident. Older adults are particularly vulnerable because symptoms may be atypical or poorly perceived. Severe hypoglycemia may also precipitate myocardial ischemia, arrhythmias, cerebrovascular events, acute cognitive deterioration and hospitalization.

The second major limitation of the class is weight gain. Because sulfonylureas increase circulating insulin, they promote a more anabolic metabolic environment, reduce glycosuria and may induce compensatory eating behavior in patients who fear or experience hypoglycemic episodes. In patients with substantial overweight or obesity, this effect is particularly relevant because it may worsen the pathophysiological substrate of type 2 diabetes mellitus by aggravating insulin resistance and making the overall treatment strategy less coherent.

Skin reactions, gastrointestinal disorders, hematological abnormalities or liver abnormalities may occur more rarely, but in clinical practice these events are less important than management of hypoglycemic risk. Another consideration that should not be overlooked is the potential false impression of simplicity. Precisely because they are oral tablets and require no complex devices, sulfonylureas tend to be perceived as “routine” medications, although they actually require much more rigorous education than other oral glucose-lowering medications with a low risk of hypoglycemia.

The safety of the class cannot be assessed without considering differences among agents. Glibenclamide raises the greatest concern for prolonged hypoglycemia and is therefore discouraged in various geriatric settings. Glimepiride and gliclazide generally have a more favorable profile, but they are not risk-free. Even with these agents, the most common error is using excessive doses in individuals whose declining glomerular filtration rate, weight loss, frailty or reduced food intake has already altered the benefit-risk balance.

In summary, the class is safe only when it is selectively safe, meaning when it is prescribed to people who can manage and tolerate it. The absence of technical complexity must never obscure the fact that sulfonylureas are among the oral antidiabetic medications with the greatest potential for preventable acute harm.

The most clinically important interactions of sulfonylureas are those that increase the risk of hypoglycemia. Some medications may enhance their effect, others may mask adrenergic symptoms of hypoglycemia, and still others may alter liver or kidney function and increase exposure to the agent. In practice, the most important point is not to memorize sterile lists, but to recognize the major risk settings: reduced food intake, kidney failure, alcohol consumption, polypharmacy in older adults and intercurrent illness.

Alcohol is particularly relevant because it reduces the liver's capacity to sustain gluconeogenesis and may promote hypoglycemic episodes, especially when consumed while fasting or in large amounts. A patient who drinks in the evening, eats little and takes a long-acting sulfonylurea creates a high-risk combination for nocturnal or morning hypoglycemia. Counseling must be very concrete. It is not enough to say “avoid alcohol” in general terms; clinicians must explain when and why the risk increases.

Irregular meals also constitute a genuine functional interaction with the medication. Skipping breakfast, delaying lunch, following drastic diets, observing religious fasts or having anorexia due to acute illness radically changes treatment safety. A sulfonylurea does not have the physiological brake that characterizes glucose-dependent incretin therapies. If the meal is omitted, the medication continues to stimulate the pancreas according to its own pharmacokinetics rather than the metabolic appropriateness of the moment.

Pharmacological interactions in the strict sense also include agents that displace sulfonylureas from protein binding, alter their metabolism or affect kidney function, but in real life the risk is often determined by a combination of factors rather than a single classic interaction. An antibiotic in an older adult with reduced food intake and mild kidney failure may be more dangerous because of the context than because of pure molecular pharmacology. Treatment review is therefore essential when a patient starts a new therapy or develops an intercurrent illness.

Beta-blockers warrant specific mention because they may attenuate the perception of some symptoms of hypoglycemia, particularly palpitations and tremor, making the onset of a hypoglycemic episode more subtle. This does not mean that they are absolutely contraindicated, but that they require greater education and monitoring. Similarly, a patient with autonomic neuropathy may have an attenuated adrenergic response and recognize the event only at a late stage.

Interactions should therefore be understood broadly: any factor that increases insulin relative to the available carbohydrate substrate or reduces the body's ability to compensate for hypoglycemia can transform routine treatment into hazardous treatment. This functional interpretation is more useful to the clinician than simple memorization of lists.

Older adults represent the clinical setting in which sulfonylureas require the greatest caution. Aging combines several risk factors: reduced kidney function, greater variability in food intake, cognitive decline, polypharmacy, an attenuated counterregulatory response and reduced ability to recognize the symptoms of hypoglycemia promptly. Agent selection, starting dose and glycemic target should therefore be more conservative in older people. Glibenclamide, or glyburide, in particular is generally considered inappropriate because of its risk of prolonged hypoglycemia.

In chronic kidney disease, the class should be used only with extreme caution, and not all agents are equivalent. The kidney contributes to the clearance of several medications and metabolites in the class, while reduced glomerular filtration also decreases degradation of endogenous insulin, amplifying hypoglycemic potential. Contemporary recommendations emphasize that when a sulfonylurea is necessary in the presence of kidney failure, a low dose, slow titration and close monitoring are required. In more advanced disease, alternatives with a lower risk of hypoglycemia are often preferable.

Liver disease also changes the safety profile. The liver contributes both to the metabolism of some sulfonylureas and to compensatory gluconeogenesis during hypoglycemia. A patient with hepatic impairment may therefore face dual vulnerability: greater exposure to the medication and a reduced ability to correct declining blood glucose spontaneously. Chronic liver disease is also often associated with malnutrition, sarcopenia and reduced metabolic reserve, factors that further amplify risk.

The class tends to become less attractive in patients with nutritional frailty, weight loss or frequent intercurrent illnesses. A sulfonylurea prescribed months or years earlier in a stable patient may suddenly become inappropriate after hospitalization, cancer, organ failure, reduced appetite or a series of hypoglycemic episodes. This illustrates why treatment should not be judged only at initiation, but reassessed over time.

Finally, there are specialist settings in which some sulfonylureas may be exceptionally advantageous, such as certain forms of monogenic diabetes. In that case, the assessment is completely different and is based on specific genetic and molecular mechanisms. Outside these settings, however, the general rule remains that special populations are not those in whom the medication should be prescribed more readily, but those in whom the reason for continuing to select it must be justified more rigorously.

The most traditional combination is metformin plus a sulfonylurea. From a pathophysiological perspective, this is a sensible combination because it pairs the reduction in hepatic glucose production achieved with metformin with stimulation of insulin secretion mediated by the sulfonylurea. For many years, this was one of the most widely used combinations worldwide and it remains common today. Glycemic efficacy is good, but the trade-off is an increased risk of hypoglycemia and a less favorable weight profile than combinations with newer classes.

When sulfonylureas are added to medications with a low hypoglycemic risk, such as metformin, dipeptidyl peptidase 4 inhibitors or sometimes sodium-glucose cotransporter 2 inhibitors, responsibility for the hypoglycemic risk rests almost entirely with the sulfonylurea. Introducing a sulfonylurea into a multidrug regimen therefore qualitatively changes the nature of treatment. A patient who until that point had taken medications that essentially do not cause hypoglycemia enters a phase in which they must know the symptoms, have access to fast-acting carbohydrates and understand what to do if a meal is delayed or physical activity increases.

Combination with insulin requires even greater caution. During the early stages of insulin initiation, particularly when only basal insulin is introduced, some clinicians temporarily continue the sulfonylurea to exploit residual secretion and improve control. As the insulin regimen is intensified, however, the benefit of the sulfonylurea tends to decline while the risk of hypoglycemia increases. In many patients, progression toward more complex insulin regimens therefore entails reducing or discontinuing the secretagogue.

Sulfonylureas do not fit well with the modern concept of treatment centered on weight, cardiorenal protection and minimization of hypoglycemic risk. If the patient needs a glucagon-like peptide 1 receptor agonist or sodium-glucose cotransporter 2 inhibitor for specific benefits, the sulfonylurea may still be present as glycemic support, but it is often the most logical candidate for progressive dose reduction or replacement once the new regimen begins to work.

Strategically, therefore, the class is more useful as a low-cost tool for glycemic intensification than as a structural component of modern organ-protection algorithms. The most rational use involves employing it when needed, at the minimum effective dose, and continually reassessing its necessity as the patient's clinical profile evolves or more suitable alternatives become available.

Monitoring sulfonylurea therapy cannot be limited to glycated hemoglobin. Glycemic control naturally remains important, but the most critical indicator of good management of the class is the absence of clinically significant hypoglycemia. A patient whose glycated hemoglobin improves by one percentage point at the cost of frequent hypoglycemic episodes, marked weight gain or a constant fear of eating outside scheduled times is not receiving genuinely well-managed therapy.

The first component of monitoring is therefore systematic assessment of symptoms and circumstances. Clinicians should ask about tremor, sudden hunger, sweating, episodes of confusion, nocturnal awakenings, morning fatigue, frequent corrective snacks, transient cognitive lapses or accidental events consistent with unrecognized hypoglycemia. In patients who use blood glucose self-monitoring or continuous glucose monitoring, these data can be integrated very usefully, but the clinical history remains fundamental.

The second component is surveillance of kidney function. A patient who has been on stable therapy for years may suddenly become more exposed when glomerular filtration declines, even moderately, or after an episode of dehydration, infection, heart failure or use of medications that worsen kidney function. Periodic monitoring of creatinine and estimated glomerular filtration rate is therefore not a bureaucratic exercise, but a safety measure.

The third component is therapeutic education. Every patient taking a sulfonylurea should know how to treat mild hypoglycemia, which fast-acting carbohydrates to use, when to repeat blood glucose measurement, when to seek help and when the risk of recurrence requires prolonged observation. Patients should also know that skipping meals, drinking alcohol without eating, suddenly increasing physical activity or failing to adapt treatment during an intercurrent illness can be dangerous.

Monitoring should also reassess body weight and the consistency of treatment with overall goals. If the patient gains weight, develops more severe obesity, enters a phase of frailty or requires medications with specific cardiorenal benefits, continuation of the sulfonylurea should be questioned. In other words, monitoring is not merely intended to “check that everything is going well,” but to determine whether the medication still makes sense.

Prevention of hypoglycemia is the true core of follow-up. In this regard, sulfonylureas require more active medicine than their simple appearance might suggest. An oral tablet may demand more intensive education and clinical surveillance than other therapies that are pharmacologically more sophisticated but physiologically safer.

Sulfonylureas now occupy a paradoxical but highly instructive position in the treatment of type 2 diabetes mellitus. On the one hand, they are effective, inexpensive, universally familiar medications capable of consistently reducing glycated hemoglobin. On the other hand, they belong to a therapeutic generation in which success was defined almost exclusively by the glycemic value, whereas contemporary diabetology demands much more: safety from hypoglycemia, weight neutrality or benefit, cardiovascular protection, kidney protection and adaptability to vulnerable populations.

For this reason, the future role of the class depends less on its intrinsic potency than on the precision with which the patient is selected. In a relatively young person with regular meals, preserved kidney function, residual beta-cell function and a need for an effective low-cost medication, a modern sulfonylurea may still be a reasonable choice. In a frail older adult with chronic kidney disease, fall risk and less stringent glycemic goals, the same class may become an irrational or even dangerous choice.

The future of sulfonylureas does not appear to involve a return to center stage, but rather a progressive redefinition of their place. They will probably continue to be used in resource-limited healthcare systems, in settings where glucose reduction is the immediate priority or in specific clinical niches. At the same time, the general trend of international algorithms is to restrict their use when alternatives with a better overall benefit-risk profile are available.

The most important clinical lesson is that “old medication” should not be confused with “useless medication,” but neither should “effective medication” be confused with “optimal medication.” Sulfonylureas remain useful when they are selected for a specific reason, with an appropriate agent, at a cautious dose and in a patient capable of managing the risk. Outside this framework, their principal historical legacy also becomes their principal limitation: they lower blood glucose well, but do so through a mechanism that places a much greater responsibility on the clinician for selection, education and monitoring than was believed in the past.